StreetAlpha.app
Home › Stocks › HALO

Halozyme Therapeutics, Inc. (HALO)

Healthcare
$91.35
▼ −1.82%
LAST CLOSE · NOV 20

Halozyme licenses its ENHANZE drug delivery technology to biopharmaceutical companies and sells its own Hylenex and XYOSTED products. It last closed at $91.35 on Nov 20, down 1.82% on the day. The next earnings report for HALO is expected around Wed, Jan 27, 2027. For the quarter ended Sep 2026, HALO reported EPS of $2.01 on revenue of $493.0M, with revenue up 39.2% from a year ago. Over its last 8 reports the stock moved an average of 8.8% the session after earnings. Over the last 12 months HALO insiders bought $0 of stock on the open market and sold $50.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is HALO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold HALO.

Key Stats

Last 12 months
Results
Revenue
$1.8B
+45.0% vs a year ago
Net income
$485.4M
−18.5% vs a year ago
EPS (diluted)
$4.00
−15.6% vs a year ago
Free cash flow
$885.9M
49.1% margin
Valuation
Market cap
$10.4B
114.0M shares
P/E
22.8
Price over 12 month EPS
Price to sales
5.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.0B
At Sep 30
Debt
$3.3B
At Sep 30
Shareholder equity
−$55.2M
Buybacks
$400.0M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $443.3M$443.3MFY2021FY2022: $660.1M$660.1MFY2022FY2023: $829.3M$829.3MFY2023FY2024: $1.0B$1.0BFY2024FY2025: $1.4B$1.4BFY2025

From HALO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 27
Estimated date · Time not announced
Reported EPS
$2.01
Quarter ended Sep 2026
Year ago EPS
$1.43
+40.6% on a GAAP basis
Revenue
$493.0M
+39.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.06Dec '24Mar 2025: $0.93Mar '25Jun 2025: $1.33Jun '25Sep 2025: $1.43Sep '25Dec 2025: -$1.12Dec '25Mar 2026: $1.22Mar '26Jun 2026: $1.90Jun '26Sep 2026: $2.01Sep '26Latest $2.01
Revenue by quarter
Dec 2024: $298.0MDec '24Mar 2025: $264.9MMar '25Jun 2025: $325.7MJun '25Sep 2025: $354.3MSep '25Dec 2025: $451.8MDec '25Mar 2026: $376.7MMar '26Jun 2026: $481.0MJun '26Sep 2026: $493.0MSep '26Latest $493.0M
How HALO moved after its last 8 reports
Average move the session after a report ±8.8%
Nov 5, 2026After the close−15.7%
Aug 6, 2026After the close+20.2%
May 11, 2026After the close+6.8%
Jan 28, 2026Time not announced+3.7%
Nov 3, 2025After the close+2.8%
Aug 5, 2025After the close+2.5%
May 6, 2025After the close+18.1%
Feb 18, 2025After the close−0.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on HALOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on HALO: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $81.00
JPMorgan Chase & CoNew target
Nov 21 $81.00
HC WainwrightReiterated
Nov 21Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on HALO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on HALO

Technical Analysis

HALO · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 23% below its 20 day and 24% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 20), oversold. The nearest support is the Pivot S1 at $90.21, and the nearest resistance the Pivot at $91.93.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 4.5%/day
Key levels
$134.0052 week high+46.7%
$113.2150 day average+23.9%
$112.2220 day average+22.8%
$104.78Swing high (Aug 11)+14.7%
$103.16100 day average+12.9%
$93.06Pivot R1+1.9%
$91.93Pivot+0.6%
$91.35Last close
$90.21Pivot S1−1.2%
$85.89200 day average−6.0%
$81.21Swing low (Jul 30)−11.1%
$61.2352 week low−33.0%
Indicators
RSI (14)20.02Oversold below 30Oversold
MACD-6.81Below its signal lineBearish
Stochastic2.7Near the bottom of its rangeOversold
ADX (14)45.0Strong downtrend
Williams %R-98.6Oversold below −80, overbought above −20Oversold
CCI (20)-94.1Oversold below −100, overbought above 100Neutral
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$4.12Typical daily range, 4.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for HALO

What happened before

See how HALO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow HALO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How HALO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for HALOHow many large options trades hit HALO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

HALO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲423 buying vs 313 selling
  • ▼Held by funds -28.6 pts
  • ▲Funds holding +102
  • ▲Superinvestors: 4 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding792690+14.8%
In funds' top 102110+110.0%
Held by funds121.4%149.9%−28.6 pts
New / increased164 / 259101 / 275+12.5%
Reduced / sold out253 / 60209 / 75+10.2%
Put/call ratio0.620.91−31.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HALO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

HALO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$50.3M23 sales · 5 insiders
96% of the selling was under pre-arranged trading plans.
2025-12 sold $1.2M2026-01 sold $141K2026-02 sold $3.9M2026-03 sold $5.4M2026-04 sold $3.2M2026-05 sold $3.5M2026-06 sold $4.0M2026-07 sold $278K2026-08 sold $6.4M2026-09 sold $8.5M2026-10 sold $7.2M2026-11 sold $6.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Matthew L. PosardDirectorSale plan5,000$96.43$482K
Nov 16Helen TorleyPresident And CEOSale plan60,000$100.01$6.0M
Oct 8Helen TorleyPresident And CEOSale plan60,000$110.17$6.6M
Oct 1Matthew L. PosardDirectorSale plan5,230$108.54$568K
Sep 16Matthew L. PosardDirectorSale plan18,996$107.74$2.0M
Sep 11Helen TorleyPresident And CEOSale plan60,000$107.28$6.4M
Every insider buy and sale for HALO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See HALO insider trades →

From SEC Form 4 filings by HALO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HALO is in one of them and how their past HALO trades turned out.

HALO in the AI portfolios
Loading…

HALO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HALO in an article yet. Here's the latest on the wider market.

HALO in the news

HALO Congress Trades

All congress trades →
Trades, 12 months
2
Buys
1
50%
Sells
1
50%
People
1
Last filed Oct 12
Who traded HALO · since 2017
Latest 5 filings of 11
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded Mar 9, 2026Filed Apr 7, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Mar 24, 2025Filed Apr 7, 2025
Josh GottheimerSell (partial)
$1K – $15KTraded Sep 9, 2024Filed Oct 3, 2024
$15K – $50KTraded Jul 12, 2023Filed Aug 13, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KMar 9, 2026Apr 7, 202629 d
Gilbert CisnerosD · CASell (partial)$1K – $15KMar 24, 2025Apr 7, 202514 d
Josh GottheimerD · NJSell (partial)$1K – $15KSep 9, 2024Oct 3, 202424 d
Dan GoldmanD · NYSell$15K – $50KJul 12, 2023Aug 13, 202332 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California. It licenses its ENHANZE drug delivery technology, built on a patented enzyme, to drugmakers that want to deliver injected medicines under the skin instead of through an IV. The company also develops hyperconcentrated drug formulations and auto-injector devices with pharmaceutical partners, and it sells its own Hylenex and XYOSTED products.

Headquarters
San Diego, CA
Founded
1998